Evidence map›Paper›PMID 31594548›Full record

ArticleBMC cancer2019

Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.

Zhanglin Zhang, Zhiwei Chen, Mei Jiang, Shuyuan Liu, Yang Guo, Lagen Wan, Fei Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhanglin ZhangDepartment of Clinical Laboratory, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Zhiwei ChenInstitute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Nanchang, 330006, China.
Mei JiangDepartment of Clinical Laboratory, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Shuyuan LiuDepartment of Clinical Laboratory, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Yang GuoDepartment of Clinical Laboratory, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Lagen WanDepartment of Clinical Laboratory, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Fei LiInstitute of Hematology, Academy of Clinical Medicine of Jiangxi Province, Nanchang, 330006, China. yx021021@sina.com.ORCID http://orcid.org/0000-0002-7765-5975
Nanchang University · CNJiangxi University of Traditional Chinese Medicine · CN

Funding

Science and Technology Cooperation Program of Jiangxi Province 20151BDH80043the National Natural Science Foundation of China 81560036, 81560034the National Natural Science Foundation of China 81760539
6 · The paper itself

Abstract

backgroundAlthough extensive use of tyrosine kinase inhibitors has resulted in high and durable response rate and prolonged survival time in patients with BCR-ABL1 positive chronic myeloid leukemia (CML) and acute leukemia, relapse and drug resistance still remain big challenges for clinicians. Monitoring the expression of BCR-ABL1 fusion gene and identifying ABL kinase mutations are effective means to predict disease relapse and resistance. However, the prognostic impact of BCR-ABL1 signal patterns detected by fluorescence in situ hybridization (FISH) remains largely unaddressed.

methodsBCR-ABL1 signal patterns were analyzed using FISH in 243 CML-chronic phase (CML-CP), 17 CML-blast phase (CML-BP) and 52 BCR-ABL1 positive acute lymphoblastic leukemia (ALL) patients.

resultsThe patterns of BCR-ABL1 signals presented complexity and diversity. A total of 12 BCR-ABL1 signals were observed in this cohort, including 1R1G2F, 1R1G1F, 2R1G1F, 1R2G1F, 2R2G1F, 1R2G2F, 1R1G3F, 1G3F, 2G3F, 1G4F, 1R1G4F and 1R4F. Complex BCR-ABL1 signal patterns (≥ two types of signal patterns) were observed in 52.9% (n = 9) of the CML-BP patients, followed by 30.8% (n = 16) of the ALL patients and only 2.1% (n = 5) of the CML-CP patients. More importantly, five clonal evolution patterns related to disease progression and relapse were observed, and patients with complex BCR-ABL1 signal patterns had a poorer overall survival (OS) time compared with those with single patterns (5.0 vs.15.0 months, p = 0.006).

conclusionsOur data showed that complex BCR-ABL1 signal patterns were associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia. Monitoring BCR-ABL1 signal patterns might be an effective means to provide prognostic guidance and treatment choices for these patients.

Indexed as

AdolescentAdultAgedClonal EvolutionDisease ProgressionFemaleFusion Proteins, bcr-ablHumansIn Situ Hybridization, FluorescenceLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisSurvival RateYoung AdultFusion Proteins, bcr-ablBCR-ABL1Clonal evolutionFluorescence in situ hybridizationPrognosis

Identifiers

PMID31594548
PMCPMC6781398
OpenAlexW2979552489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.